|Mr. Stephen R. Davis J.D.||Chief Exec. Officer, Pres and Director||1.13M||N/A||56|
|Mr. Todd S. Young||Chief Financial Officer and Exec. VP||409.1k||N/A||45|
|Mr. Glenn F. Baity||Exec. VP, Gen. Counsel and Sec.||N/A||N/A||47|
|Dr. Srdjan R. Stankovic M.D., M.S.P.H.||Head of R&D and Exec. VP||709.79k||N/A||60|
|Mr. James A. Nash||Sr. VP of Technology Devel. & Operations||N/A||N/A||66|
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinsons disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimers disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc.’s ISS Governance QualityScore as of September 1, 2017 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 7.